Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 35 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $70.874 million which beat the analyst consensus estimate of $60.850 million by 16.47 percent. This is a 35.26 percent increase over sales of $52.400 million the same period last year.